Title: Trastuzumab Industry in China 2018
1Investigation Report on China Trastuzumab Market,
2009-2018byResearch In China
- Explore all reports for Life Sciences market
- _at_ http//www.chinamarketresearchreports.com/cat/li
fe-sciences.html .
2Investigation Report on China Trastuzumab Market,
2009-2018
- The collection of Life Sciences market research
reports has a new addition of Investigation
Report on China Trastuzumab Market, 2009-2018On
chinamarketresearchreports.com. Trastuzumab is a
monoclonal antibody that interferes with the
HER2/neu receptor. Its main use is to treat
certain breast cancers. Trastuzumab has a major
impact in the treatment of HER2positive
metastatic breast cancers. - In China, less than 10 of women can get mammary
diseases inspection every year for the limitation
of medical conditions and lack of knowledge.
Therefore, only 20 of breast cancers is detected
at an early stage in China while 80 is detected
at an early stage in the U.S.A. - The incidence of breast cancers ranks the first
in malignant tumors. According to incomplete
statistics, the incidence number of breast
cancers exceeds 200,000 every year in China. By
the end of 2013, the number of living breast
cancer patients exceeded 500,000, above 1/3 of
which were metastatic breast cancers. The
incidence and mortality rates of breast cancers
differ from urban to rural areas in China. - Inquire for discount _at_ http//www.chinamarketresea
rchreports.com/contacts/inquiry.php?name114713
3Investigation Report on China Trastuzumab Market,
2009-2018
- In recent 10 years, the incidence of breast
cancers in cities obviously increases but the
mortality rate remains stable. However, the
incidence and mortality rates of breast cancers
in rural areas present obvious uprising trend.
The number of breast cancer patients in cities is
increasing, especially in young women groups. It
is mainly caused by the change of lifestyle and
diet habits and the incidence growth of other
mammary diseases like fibroma. Take Fujian as an
instance, from 1970s to the early 21 century, the
mortality rate of breast cancers in Fujian
presents an upward trend. The mortality rates in
19731975, 19901992 and 20042005 are separately
31.6/million, 34.2/million and 44.6/million. In
2011, the mortality rate of women breast cancer
patients was 70.7/million in Fujian. Obviously,
the mortality rate doubled during 20052011. - In China sample hospital market, the market share
of trastuzumab is completely taken by Shanghai
Roche and GENENTECH. During 20052013, the CAGR of
market size of trastuzumab in sample hospitals
exceeded 60. The unit retail price maintains CNY
20,000 (USD 3,300) or more. - Complete report is available _at_
http//www.chinamarketresearchreports.com/114713.h
tml -
4Investigation Report on China Trastuzumab Market,
2009-2018
- The patent of trastuzumab will expire in 2014.
The huge profit margin and market potential
attract many generic drug manufacturers. CRI sees
many generic drugs will enter global market after
2015. According to CRI's investigation, many
generic drug companies add trastuzumab to the RD
list, some of which has certain achievements. - Through this report, the readers can acquire the
following information - Market Share of Major Trastuzumab Manufacturers
in Sample Hospitals in China - Sales price of Trastuzumab in Hospital Market in
China - Major Trastuzumab enterprises in China
- Market share of Trastuzumab by dosage form in
hospital market in China - Incidence of breast cancers in China
- Progress of trastuzumab generic drugs
- Prospect of China trastuzumab market
- Inquire for discount _at_ http//www.chinamarketresea
rchreports.com/contacts/inquiry.php?name114713 -
5Investigation Report on China Trastuzumab Market,
2009-2018
- The following enterprises and people are
recommended to purchase this report - Trastuzumab API and finished product
manufacturers - Medical Institutions
- Investors/research agencies focusing on
trastuzumab market - Table of Contents
- 1 Relevant Concepts of Trastuzumab1.1
Indication1.2 Sales Status on the Global Market - 2 Market Overview of Trastuzumab in China,
2009-20132.1 Patent Status2.2 Major
Manufacturers2.3 Market Size - 3 Investigation on Sales Value of Trastuzumab in
China, 2009-20133.1 Total Sales ValueComplete
report is available _at_ http//www.chinamarketresea
rchreports.com/114713.html -
6Investigation Report on China Trastuzumab Market,
2009-2018
- 4 Investigation on Market Share of Major
Trastuzumab Manufacturers in China, 2009-20134.1
Market Share by Sales Value4.2 Market Share by
Sales Volume - 5 Investigation on Market Size of Trastuzumab by
Dosage Form in China , 2009-20135.1 Market Share
by Sales Value and Dosage Form5.2 Market Share
by Sales Volume and Dosage Form - 6 Reference Price of Trastuzumab in Hospital
Market in China, 20136.1 Trastuzumab Produced by
Shanghai Roche (Brand Name Herceptin)6.2
Trastuzumab Produced by GENENTECH (Brand Name
Herceptin) - 7 Analysis on Major Trastuzumab Manufacturers in
China, 2009-20137.1 Shanghai Roche
Pharmaceuticals Ltd.7.2 GENENTECH (Subsidiary of
Roche) - Inquire for discount _at_ http//www.chinamarketresea
rchreports.com/contacts/inquiry.php?name114713 -
7Investigation Report on China Trastuzumab Market,
2009-2018
- 8 Prospect of China Trastuzumab Market,
2014-20188.1 Forecast on Incidence of Mammary
Cancer8.2 Forecast on Market Size8.3 Forecast
on Competition Pattern - List of Charts
- Chart Trastuzumab Products Approved to Market in
China, 2014Chart Forecast on Market Size of
Hospital-use Trastuzumab in China,
2014-2018Chart Sales Value of Trastuzumab in
Global Market, 2009-2013Chart Sales Value of
Trastuzumab in Hospital Market in China,
2009-2013Chart Sales Value of Trastuzumab by
Region in China, 2009-2013Chart Market Share of
Trastuzumab Enterprises by Sales Value in China,
2009-2013Chart Price of Trastuzumab Produced by
GENENTECH(US) in Hospital Market, 2009-2013Chart
Price of Trastuzumab Produced by Shanghai Roche
in Hospital - Complete report is available _at_
http//www.chinamarketresearchreports.com/114713.h
tml -
8Investigation Report on China Trastuzumab Market,
2009-2018